# A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Clinical trial · Eli Lilly and Company

- Archive id: nct:NCT05882045
- Published: 2023-05-31
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05882045
- Source URL: https://clinicaltrials.gov/study/NCT05882045
- Provenance: clinicaltrials

## Abstract

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: TRIUMPH-3
- status: COMPLETED
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 1946
- sponsor: Eli Lilly and Company
- conditions: Obesity; Cardiovascular Diseases
- interventions: DRUG: Retatrutide; DRUG: Placebo
- start date: 2023-05-30
- start date type: ACTUAL
- primary completion date: 2026-04-16
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.